A Qualitative and Quantitative Analysis of Protein Substitution in Human Burn Wounds by Joneidi-Jafari, Hamid et al.
A Qualitative and Quantitative Analysis of Protein
Substitution in Human Burn Wounds
Hamid Joneidi-Jafari, MD,a Adrien Daigeler, MD,b Joerg Hauser, MD,b Hans-Ulrich
Steinau, MD,b Walter Klatte,c Ulrich Fischer,c and Marcus Lehnhardt, MDd
aDepartment of Surgery, BG-University Hospital Bergmannsheil, Ruhr University Bochum,
Germany; bDepartment of Plastic Surgery, Burn Center, Handsurgery, Sarcoma Reference Cen-
ter, BG-University Hospital Bergmannsheil, Ruhr University Bochum, Germany; cBiotest Pharma
GmbH, Dreieich, Germany; and dDepartment of Hand, Plastic and Reconstructive Surgery, Burn
Centre, BG Trauma Centre, Ludwigshafen, Germany.
Correspondence: hamid.joneidi@ruhr-uni-bochum.de
Published September 29, 2009
Objective: In major burn wounds of more than 15% total burn surface area mediator-
associated reactions lead to capillary leak resulting in critical condition. Little is known
about the efﬁciency of protein substitution. We quantiﬁed and qualiﬁed the systemic and
local protein loss in burn patients during protein substitution, comparing fresh frozen
plasma and the human serum protein solution Biseko. Methods: In 40 patients suffering
from second-degree burn wounds with the total burn surface area between 20% and
60%, immediately after admission a deﬁned wound surface area was enclosed with in
a wound chamber. Wound ﬂuid and serum samples were collected in 8 hour intervals
for 2 days. Samples were analyzed for total protein, albumin, immunoglobulins -A, -G,
-M, clotting parameters, c-reactive protein, and white blood cells. Protein substitution
started 24 hour posttrauma. In a randomized pattern, patients received equal volumes of
fresh frozen plasma or Biseko. Results: Total protein and albumin accumulated in high
concentrationsinwoundﬂuid.Withbeginningoffreshfrozenplasmasubstitutiononday
2 posttrauma, serum total protein (1.7 g–3.9 g) and albumin (1.3 g–3.4 g) concentrations
increased. Substitution of Biseko resulted in a stronger increase (serum total protein
1.8 g to 4.5 g, albumin 0.9 g to 3.4 g). Wound ﬂuid concentrations revealed similar
change patterns. Immunoglobulins showed higher serum levels in the Biseko group. C-
reactive protein and white blood cell values indicated a lower immunological reaction in
the Biseko group. Conclusions: Substitution of human protein solutions such as Biseko
can result in signiﬁcantly higher serum protein and albumin concentrations as well
as lower infection parameters. Higher serum immunoglobulins could help to decrease
potential immunodeﬁciency.
Severeburninjuriesofmorethan15%totalbodysurfacearea(TBSA)resultinburndisease
that is characterized by electrolyte imbalance, loss of proteins followed by ﬂuid dysregu-
lations, circulatory insufﬁciency, and immunodeﬁciencies.1,2 These dysregulations arising
from capillary leakage (CL) potentially lead to systemic inﬂammatory response syndrome,
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disseminated intravascular coagulation, hypermetabolism, hypoxia, and catabolism, and
potentially result in multiorgan distress syndrome.3,4
Capillary leakage is known to appear approximately 24 hours posttrauma and is not
restricted to the burned area. The intravascular proteins extravasate mainly within the
ﬁrst 24 hours and include the important albumin (AL) fraction. The protein shift leads
to an increased extravascular oncontic pressure followed by intravascular hypovolemia,
blood thickening, and edema.1,5,6 The enormous loss of intravascular proteins can be
considered as a main reason for volume shifting. Both volume shifting and the result-
ing hypovolemia are known to be the primary cause of circulatory distress and oxygen
deﬁciency of organs that includes ischaemia, organopathy, and a high risk of local and
systemic infections.7−9 Many therapeutic efforts are known to reduce the intravascular pro-
tein deﬁciency. Treatment options are mainly based on simple volume substitution during
the ﬁrst 24 hours posttrauma according to the burned surface area and the patient’s body
weight.10 These ﬂuids may be supplemented with electrolytes, proteins, plasma expander,
fresh frozen plasma (FFP), or clotting factors, beginning 24 hours posttrauma.11,12 How-
ever, proteins are administered without exact knowledge of the quantitative or qualitative
need.
Althoughsevereinfectionsarethemaincauseofmortalityinpatientswithsevereburn
injuries, only few data are available on the presence of immunoglobulins (Igs) in human
burn wounds.13−15
This study was designed to provide qualitative and quantitative data on the amount of
protein loss in second-degree human burn wounds. In addition, we compared the effective-
ness of two different protein solutions: FFP and Biseko
 C.
MATERIAL AND METHODS
Patients
Forty patients with a burnt TBSA of 20% to 60% (32.36 ± 18.19%), ages 38 to 63 years
(48.53 ± 7.58 years), were included in the study. Exclusion criteria included inhalation
trauma, severe systemic illness (renal insufﬁciency, hepatic cirrhosis child B and C, symp-
tomatic heart insufﬁciency NYHA II, and malignant diseases), infectious diseases (human
immunodeﬁciency virus infection, hepatitis B/C), and alcohol or drug abuse.
Fluid resuscitation was calculated using the Parkland formula (4-mL Ringer/kg body
weight/% burnt TBSA) and administered by needs of the Baxter formula (50% of the
calculated volume administered in the ﬁrst 8 hours and 50% in the last 16 hours of the ﬁrst
24 hours posttrauma). None of the patients received colloidal infusions in the ﬁrst 24 hours
posttrauma. No surgical intervention was performed and no catecholamines were given
during the ﬁrst 48 hours posttrauma. None of the test persons died during the course of
the study. All burn wounds, except the wound chamber area, were treated with ﬂammazine
(silver sulphadiazine) wound dressing.
Colloid resuscitation
Protein solutions were not administered to any patient within the ﬁrst 24 hours posttrauma.
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Twenty patients received FFP and 20 patients received the protein solution Biseko
 C in
a prospective randomized matter. Equal volumes were administered to the groups, starting
24 hours posttrauma.
Biseko
 C isanisotonichumanproteinsolution.Itcontainsproteinsofthehumanserum
inphysiologicalcompositionandactiveform.One-literBiseko
 C solutioncontains50-gtotal
protein (TP), including 31-g AL, 7.1-g IgG, 1.55-g IgA, and 0.48-g IgM. It contains stable
and biologically intact Igs. Therefore, half-life, metabolism, and elimination match those
of native serum. Further ingredients are sodium ions (3.56 g), potassium ions (0.16 g),
calcium ions (0.08 g), magnesium ions (0.02 g), chloride ions (3.65 g), and water for
injections.
The administered volumes were determined according to the Slater-formula (75 mL/
kg/24 hours).16 Although the volume of protein substitution was calculated, the volume
infused was titrated to maintain an adequate urine output (minimum 0.5–1 mL/kg/hour).
Chamber design
Two wound chambers (TMED, Inc, Columbia, Tenn) were placed on silicon plates (14 ×
9 cm) with two 2.25 cm2 openings (1.5 × 1.5 cm2) as previously described17 (Fig 1a).
After cleansing and disinfection, silicon plates and chambers were ﬁxed to the center of the
burn wound using Enbucrilat (Histoacryl, Braun Medical AG, CH-6020 Emmenbr¨ ucke)
and ﬁlled with 2.5 mL of 0.9% sodium chloride solution. A 14 × 9c m 2 second-degree
burnt area on the anterolateral thigh was enclosed in the cutaneous vinyl chamber sys-
tem. Each patient received two chambers on one silicon plate on the wounded skin and
one chamber placed on unwounded skin as control. Chambers were placed 2 to 4 hours
posttrauma. The accumulated wound ﬂuid (WF) was harvested with a 10-mL syringe and
a 20-gauge needle every 8 hours and replaced by 2.5 mL of saline for a total time pe-
riod of 48 hours until eschar excision was performed. As in WF sampling, serum was
gained from central venous catheters (10-mL Serum Monovette
 R BraunC AG, Frankfurt,
Germany).
The study was approved by the ethical committee of the Ruhr-University (Bochum,
Germany) (registration No. 1516), and written consent was given by each patient or a legal
representative.
Collection of WF and blood samples
Wound ﬂuid was harvested in 8-hour intervals by puncture of the chambers’ superstructure.
The consistency of the WF varied from transparent liquid to ﬁbrinoid viscous.
All samples were centrifuged at 2000×g for 9 minutes at 4◦C to separate the cells
from ﬂuid. The supernatant was partitioned in aliquots, shock frozen in liquid nitrogen, and
stored at −82◦C. Samples were analyzed for TP content, AL, and the Igs A, E, G, and M.
At various time points, blood samples were analyzed for the inﬂammatory parameters—c-
reactiveprotein(CRP)andwhitebloodcell—andthecoagulationparameters—prothrombin
time, partial thromboplastin time, antithrombin concentration, and, ﬁnally, the ﬁbrinogen
concentration.
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Figure 1. Silicon plate and vinyl chambers. The applied chamber system.
Yellow coloring provides the protein content.
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Analysis of proteins
Serum TP content was measured with the biuret method (Synchron LX-System, Beckmann
Coulter, Inc, Krefeld, Germany). Serum AL was determined by the Bromcresolpurpur
method (Synchron LX-System, Beckmann Coulter, Inc). IgG, M, and A were deﬁned
nephrelometric (Immage Immunchemisystem, Beckmann Coulter, Inc). IgE was measured
with an immunoassay (Unicap, Pharmacia Diagnostics, Freiburg, Germany). Wound ﬂuid
TP content was determined with the pyragallol red method (CX-9, Beckmann Coulter,
Inc). Wound ﬂuid AL content was detected nephrelometric (Immage Immunchemisystem,
Beckmann Coulter, Inc).
Analysis of the biopsies
To verify the severity of the thermal injury and to validate the burn depth, biopsies were
takenattheedgeofthesiliconchambers.Nexttotheareaofchamberplacement,acutaneous
biopsy of 1 × 1c m 2 was taken and analyzed. The biopsies were analyzed histologically
by haematoxylin-eosin- or Hinshaw-Pearse-staining (Department of Pathology at the BG
University Hospital Bergmannsheil Bochum) (data not shown).
Calculation of TBSA and protein quantiﬁcation in serum
Protein quantiﬁcation in WF was performed by a division of measured concentrations
with the appropriate chamber volume. Because of the standard of determining the patient’s
burnt skin as a percentage of TBSA, the TBSA of each patient was calculated using the
DuBois formula, which is widely used for TBSA prediction (eg, in chemotherapy).18,19
The measured amount of protein per chamber was converted into the amount of protein per
10% burnt TBSA.
Plasma volume was calculated by means of the Retzlaff equation, with which plasma
volume in relation to height, weight, and haematocrit of patients with normal and patho-
logical haematocrit can be accurately determined.20
RESULTS
High values of the measured protein concentrations were detected at all time points in the
burn wounds. There was a marked decrease of all detected protein contents in the serum
that was contrary to WF concentrations.
Chamber volume
Each wound chamber contained 3.11 ± 1.13 mL of WF on average after an 8-hour interval
posttrauma, varying from 2.5 mL to 5.8 mL.
Total protein
Mean TP concentration in wound chambers was 0.93 ± 0.43 g/dL. According to the
correlativechambervolume,eachchambercontained0.02±0.008gofprotein.Analogous
to a 10% burnt TBSA, this is equivalent to a protein loss of 16.6 ± 8.86 g in a collection
period of 8 hours.
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Figure 2. Total protein and albumin in wound ﬂuid. Protein substitution started 24 hour post-
trauma using fresh frozen plasma.
With the introduction of FFP substitution 24 hours posttrauma, WF protein concentra-
tion nearly stagnated at about 0.7 g/dL (24 hours) (0.73 g/dL 40 hours) (Fig 2). Substitution
of Biseko
 C resulted in an increase of WF protein concentration from 0.65 g/dL after 24 h
to 1.1 g/dL from after 40 hours posttrauma (Fig 3).
Total protein concentrations in serum in the ﬁrst 24 hours posttrauma decreased in all
patients. After beginning the protein administration, TP concentrations began to rise. On
day 2 posttrauma, serum protein concentrations increased from 1.7 g/dL (24 hours) to 3.9
g/dL (40 hours) (Fig 4). Substitution of Biseko
 C resulted in an even stronger rise of serum
protein concentration from 1.8 g (24 hours) to 4.5 g (40 hours) (Fig 5).
Albumin
Overall mean AL concentration in WF was 0.62 ± 0.2 g/dL in the ﬁrst 24 hours, which
is equivalent to 0.019 ± 0.007 g per chamber, and 12.39 ± 5.87g on a 10% burnt TBSA.
This corresponds to an AL loss of 38.44 g in 10% burnt TBSA in 24 hours posttrauma. The
changes of AL values in WF were comparable with those of TP in WF (Figs 2 and 3).
FFP substitution resulted in an AL concentration increase in WF from 0.55 g/dL (24
hours) to 0.64 g/dL (40 hours), whereas substitution of Biseko
 C resulted in a stronger
increase of the AL concentration from 0.55 g/dL (24 hours) to 0.95 g/dL (40 hours)
(Figs 2 and 3).
During FFP substitution, AL concentration in serum increased from 1.3 g/dL
(24 hours) to 3.4 g/dL (40 hours) (Fig 4). In the Biseko
 C group, the starting values were
lower those in the FFP group, 0.9 g/dL (24 hours), but after the addition of Biseko
 C the
AL concentration rose to similar values 3.4 g/dL (40 hours) compared with that in the FFP
group (Fig 5).
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Figure 3. Totalproteinandalbumininwoundﬂuid.Proteinsubstitutionstarted24hourposttrauma
using Biseko.
Figure 4. Total protein and albumin in serum. Protein substitution started 24 hour posttrauma
using fresh frozen plasma.
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Figure 5. Total protein and albumin in serum. Protein substitution started 24 hour posttrauma
using Biseko.
Immunoglobulins
The highest concentrations of Igs in WF and serum were found for IgG (WF: 157.09 ±
88.58 mg/dL; serum: 396.62 ± 216.54 mg/dL), whereas the lowest concentrations were
found for IgA (WF: 57.7 ± 12 mg/dL). Correlated to 10% burnt TBSA, there was a 0.96-g
mean loss of IgG within 8 hours posttrauma (16.5 g in 24 hours).
Immunoglobulins in serum decreased until 24 hours postadmission and then stag-
nated with FFP substitution, except IgG, which revealed continuously decreasing val-
ues until the end of the measurements after 48 hours (Fig 6). In WF, IgG initially
increased, while IgA and IgM revealed constant or decreasing values (Fig 7). Af-
ter 24 hours, all Igs showed continuously decreasing values during FFP substitution
(Fig 7).
After Biseko
 C substitution, IgG, IgM, and IgA showed increasing values in serum,
whereas IgG revealed the highest rise (Fig 8). Wound ﬂuid Igs values, especially IgG,
increased after Biseko
 C substitution (Fig 9).
Coagulation parameters
Twenty-four hours posttrauma, ﬁbrinogen concentration showed increasing values in both
groups, whereas the remaining parameters revealed inconsistent progression (Figs 10–
12). After FFP substitution, PT and PTT values remained with insigniﬁcant changes
while AT III and ﬁbrinogen values slightly increased (Figs 10 and 12). After Biseko
 C
substitution at 24 hours, ﬁbrinogen concentration and PTT had increased signiﬁcantly
(Figs 11 and 12).
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Figure 6. Immunoglobulinsinwoundﬂuid.Proteinsubstitutionstarted24hourposttraumausing
fresh frozen plasma.
Figure 7. Immunoglobulins in wound ﬂuid. Protein substitution started 24 hour posttrauma using
Biseko.
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Figure 8. Immunoglobulins in serum. Protein substitution started 24 hour posttrauma using fresh
frozen plasma.
Figure 9. Immunoglobulins in serum. Protein substitution started 24 hour posttrauma using
Biseko.
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Figure 10. Coagulationparametersinserum.Proteinsubstitutionstarted24hourposttraumausing
fresh frozen plasma.
Figure 11. Coagulationparametersinserum.Proteinsubstitutionstarted24hourposttraumausing
Biseko.
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Figure 12. Fibrinogeninserum.Proteinsubstitutionstarted24hourposttraumausing
fresh frozen plasma or Biseko.
Inﬂammation parameters
Serum CRP levels continuously increased and showed similar values in both groups up
to 32 hours posttrauma (  8.5 mg/dL). While CRP peak-concentrations in the FFP group
was found 40 hours posttrauma (23 mg/dL), in the Biseko
 C group, peak value was found
48 hours posttrauma (17 mg/dL) (Figs 13 and 14).
Whitebloodcellsshowedsimilarvalues.Beginningfromaninitialpeakinbothgroups
(  19/nL), there was a decrease detectable up to 24 hours posttrauma in both the FFP and
Biseko
 C groups. From that time point, a plateau was seen in the Biseko
 C group (  7.5/nL
up to48 hoursposttrauma)anda signiﬁcantincreasein theFFP group (  13/nLat48hours
posttrauma) (Figs 13 and 14).
Biopsies
All biopsies taken conﬁrmed deep partial burnt skin (data not shown). No proteins could
be detected over unwounded skin.
DISCUSSION
In patients suffering from burn wounds with more than 15% TBSA, disorders in several
systems (eg, immune, vascular, and electrolyte system) result in a severe and unique
derangement called burn shock.11 The pathophysiology of the burn shock manifests with
the full spectrum of the complexity of the inﬂammatory response.17,21,22
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Figure 13. C-reactive protein and leucocytes in serum. Protein substitution started 24 hour post-
trauma using fresh frozen plasma.
Figure 14. C-reactive protein and leucocytes in serum. Protein substitution started 24 hour
posttrauma using Biseko.
Initially, burn shock is hypovolemic in nature and is characterized by hemodynamic
changes similar to those that occur after hemorrhage, including decreased plasma volume,
cardiac output, urine output, and an increased systemic vascular resistance, resulting in re-
duced peripheral blood ﬂow.23 The loss of intravascular proteins results from CL syndrome
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and is induced by an endothelial dysregulation, including increasing endothelial perme-
ability, hypermetabolism, protein catabolism, disseminated intravascular coagulation, and
the direct destruction of local proteins in the region of heat impact.1,24
Capillary leakage represents the end of a cascade that is initiated and inﬂuenced
not only by different mediators like histamine, prostaglandins, thromboxane, kinins, sero-
tonin, catecholamines, and oxygen radicals but also by direct mechanical stress resulting
in increasing intercellular clefts caused by in- and extracellular swelling.4 It takes place
in the region of heat impact as well as in other body regions.24 In heat-damaged body
parts, several different factors are responsible for the dispersion of circulating volume
with resulting edema, such as local destruction of endothelial continuity, local denatu-
ration and loosening of interstitial proteins, local inﬂammatory reaction, and CL.1,25−27
In body parts not damaged by heat, the oncotic pressure is most likely the main factor
in the ensuing volume shift to interstitial tissue; therefore, intravascular plasma proteins
are extremely important because they can decrease the extravasation of the circulating
ﬂuids.
Time of colloid resuscitation
Consequently, protein replacement was an important component of early formulas for
burn management.28 Considerable confusion exists concerning the role of proteins in a
resuscitation formula and is still a matter of discussion. There are mainly three schools of
thought:
1. Protein solutions should not be given within the ﬁrst 24 hours: they are not effective in
resuscitation because of shifting to the interstitium and they promote accumulation of
lung water when edema ﬂuid is being absorbed from the burn wound.12,29
2. Proteins should be given from the beginning of resuscitation, along with crystalloid, to
counter the protein deﬁciency and its disadvantages.30
3. Protein should be given after 8–12 hours postburn; resuscitation should be strictly
crystalloid in the ﬁrst 8–12 hours because of the massive extravasation of ﬂuids during
this period.7
Thisstudydemonstratesanaveragewoundproteinlossof16.6±8.86ginacollection
period of 8 hours in a 10% burnt TBSA. Total protein values measured in wound chambers
were consistently high until the end of measurements. These ﬁndings conﬁrm results of
a previous study in which a patient’s TP amount in serum is lost to a wound surface
of 20% burnt TBSA in 24 hours.31 Substitution of FFP and Biseko
 C beginning 24 hours
posttraumarisestheintravascularproteinandALconcentrationandconsecutivelyincreases
intravascular oncotic pressure. Furthermore, TP and AL concentration also increases in
WF and reveals a persistent leakage of proteins for a time period of more than 24 hours
posttrauma. The data suggest that the CL persists signiﬁcantly longer than the estimated
time of 24 hours posttrauma; however, the protein substitution results in increasing serum
values of TP and AL in both the FFP and Biseko
 C groups and, furthermore, increasing
values of Igs in the Biseko
 C group. The resulting increased intravascular oncotic pressure
andtheimmunestatusmightbebeneﬁcialforthepatient.Wethereforerecommendanearly
substitution beginning after 24 hours posttrauma although the CL persists.
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Type of resuscitations solutions
The choice of the type of protein solution in burn injuries can also be confusing. After
24 hours posttrauma, several add-ups, for example, plasma expander and colloidal or AL
solutions, are administered.32,33 Several different strategies for plasma volume expansions
are used: for example, FFP, AL, starches, gelatins, dextrans, and different human protein
compilations. At present, in most burn centers, physicians use 5%–20% AL in isotonic
crystalloid solution or FFP to increase the intravasal oncotic pressure, whereas gelatins
are less common and dextrans are only rarely used.34 Standard protein supplements result
in increased concentrations of AL and, consequently, TP. Besides the singular colloidal
supplements,proteincompilationsareusedtoelevatenotonlytheALandTPconcentrations
but also the Igs concentrations.
There are a few drawbacks that have to be accepted in using FFP. Beside its limited
availability, the cold chain may not be interrupted. FFP has a limited durability (2 years
including 4–6 months of quarantine). Before using, FFP must be thawed. A blood group–
adapted infusion and documentation, as well as a bedside test, are essential. Furthermore,
as a product of human blood, it has a marked risk of viral and bacterial infections although
several technologies for pathogen reduction of plasma reduce the risk of bacteria and virus
transmission.35,36 However,FFP’smajoradvantageisstillthecontentofhaemostaticfactors.
Biseko
 C is a compilation of human AL and the Igs A, G, and M. It has a durability of
3 years and there is no need for a blood group–adapted infusion. Even though Biseko
 C is a
human product and there is consequently a risk of viral and bacterial infections, presently,
no viral or bacterial infections after Biseko
 C infusions have been documented.
This study reveals a considerable beneﬁcial progression of serum-TP and AL concen-
trationsintheBiseko
 C group.Furthermore,wefoundaneffectiveincreaseofthesubstituted
Igs in the Biseko
 C group.
AlthoughBiseko
 C doesnotcontaincoagulationparameters,therewasapositiveeffect
on blood coagulation in this group as well. A possible reason might be associated with the
more physiologicallevel of TP and AL. In consideration of the known multiple functions of
AL, including its transportation functionality, the impact of high AL concentrations seems
understandable.37
TheregisteredsystemicinﬂammatoryparametersWBCandCRPshowedlowervalues
in the Biseko
 C group. It shows varying immunological responses in the compared groups.
Theproteinsadministereddonotinterferewiththehumoral-inducedsystemicinﬂammatory
response syndrome or CL; nevertheless, there seems to be an effect of the proteins that
leads to differing immunologic response.
In summary, commercial protein solutions like Biseko
 C are valuable alternatives to
pure AL or FFP substitution. The application might result in better conditions for the
patient in view of starting with surgical interventions on day 3 posttrauma. Further trials
withbiggerpatientgroupsarenecessarytovalidatethebeneﬁcialaspectsofdifferentprotein
solutions.
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